Listen "AbbVie Q2 2025: Immunology Power & Strategic Pipeline Moves"
Episode Synopsis
In this episode of Know What You Are Investing, we unpack AbbVie’s stellar second quarter of 2025. With total revenues surpassing $15.4B and strong performance in immunology, neuroscience, and oncology, AbbVie is showing investors a powerful vision beyond HUMIRA.🔥 What’s Inside🔹 Skyrizi and Rinvoq set to exceed $25B in 2025 combined sales🔹 Neuroscience growth led by Vraylar, QULIPTA, and VYALEV🔹 Oncology resilience and aesthetic segment headwinds🔹 30+ business development deals including obesity, CAR-T, ADCs🔹 Strategic investments in U.S. manufacturing & next-gen therapies🔹 IRA updates and tariff outlook🔹 Analyst Q&A highlights and Q3–Q4 guidance🎯 Whether you’re an investor, analyst, or healthcare innovation enthusiast — this is your full breakdown of how AbbVie is engineering its next decade of growth.🎙️ Know What You Are Investing Podcast🔍 What they do🚀 How they grow📊 Why it matters